Evidence map›Paper›PMID 19318435›Full record

Trial reportCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2009

Components of metabolic syndrome and metachronous colorectal neoplasia.

Erin L Ashbeck, Elizabeth T Jacobs, María Elena Martínez, Eugene W Gerner, Peter Lance, Patricia A Thompson

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Erin L AshbeckArizona Cancer Center, Tucson, AZ 85724, USA.
Elizabeth T Jacobs
María Elena Martínez
Eugene W Gerner
Peter Lance
Patricia A Thompson
Immunovaccine (Canada) · CAUniversity of Arizona · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
WHEAT BRAN FIBER SUPPLEMENTS ON THE RECURRENCE OF COLONIC ADENOMASP01CA041108 · NCI · UNIVERSITY OF ARIZONA · PI HAMILTON, STANLEY R. · 1986 to 2009
$38.8M
SPORE in Gastrointestinal CancerP50CA095060 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2002 to 2012
$25.3M
RESISTANCE TO BILE ACID INDUCED APOPTOSISP01CA072008 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 1997 to 2005
$6.9M
Prevention of APC-Dependent Intestinal CarcinogenesisR01CA123065 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2007 to 2011
$1.6M
SERUM SELENIUM AND LARGE BOWEL ADENOMA RISKR03CA077145 · NCI · DARTMOUTH COLLEGE · PI KARAGAS, MARGARET RITA · 1997 to 1998
–
NCI NIH HHS 1K07CA10629-01A1NCI NIH HHS CA-23074NCI NIH HHS CA-41108NCI NIH HHS CA-77145NCI NIH HHS P01 CA041108NCI NIH HHS P01 CA072008NCI NIH HHS P30 CA023074NCI NIH HHS P50 CA095060NCI NIH HHS R01 CA123065
6 · The paper itself

Abstract

backgroundThe consistent association between obesity and colorectal cancer is thought to be explained by metabolic disturbances common, but not exclusive, to the obese.

methodsWe assessed the relation between metachronous neoplasia and the components of metabolic syndrome (MetS) as defined by the National Cholesterol Education Program's Adult Treatment Panel III in 2,392 participants of two previously conducted chemoprevention trials. Waist circumference, fasting plasma glucose, trigylcerides, high-density lipoprotein, and systolic and diastolic blood pressure were measured at baseline.

resultsMetS classification was associated with increased odds of metachronous neoplasia among women [odds ratio (OR), 1.37; 95% confidence interval (95% CI), 1.01-1.85] but not among men (OR, 0.99; 95% CI, 0.81-1.21). High waist circumference in men (OR, 1.41; 95% CI, 1.15-1.72) and women (OR, 1.41; 95% CI, 1.05-1.90) and elevated fasting glucose in women (OR, 1.46; 95% CI, 1.09-1.96), as defined by Adult Treatment Panel III cutpoints, were associated with increased odds, whereas none of the other criteria were independently associated with metachronous neoplasia. When each trait was evaluated using quartiles, elevated glucose among women and large waist circumference among men were significantly associated with metachronous lesions. Exploratory analysis of waist circumference and fasting glucose suggested an interaction, where only the combination of large waist circumference and elevated glucose conferred significant increased odds of metachronous neoplasia among both men (OR, 1.36; 95% CI, 1.04-1.78; P(interaction) = 0.08) and women (OR, 1.83; 95% CI, 1.26-2.67; P(interaction) = 0.12).

conclusionsThese results suggest that, of the specific components of MetS, those that capture impaired glucose uptake increased the odds of metachronous neoplasia.

Indexed as

AdenomaAgedBlood GlucoseBlood PressureBody Mass IndexCholesterolColorectal NeoplasmsFemaleHumansMaleMetabolic SyndromeObesityPlacebosRisk FactorsWaist CircumferenceBlood GlucoseCholesterolPlacebos

Identifiers

PMID19318435
PMCPMC2737414
OpenAlexW2133544901

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.